According to the research, the reduction in hepatic ceruloplasmin leads to the replenishment of hepatic copper levels, hence mitigating liver steatosis through the modulation of the copper-SOC1-AMPK signaling pathway in a mouse model of NAFLD [78]. The gene discussed is CP; the disease is metabolic dysfunction-associated steatotic liver disease.